INCB161734 — Investigational Agent
KRAS Inhibitor · Phase 1 · Incyte
Mechanism of Action
Oral selective inhibitor of KRAS G12D, targeting the aspartate-mutant GTPase in both active (GTP-bound) and inactive states to block downstream MAPK/PI3K signaling.
Investigational Indications
- KRAS G12D-mutant pancreatic ductal adenocarcinoma
- KRAS G12D-mutant colorectal cancer
- Other KRAS G12D solid tumors